Stonegate Healthcare Reviews Retinitis Pigmentosa

Key Takeaways

  • Retinitis Pigmentosa (RP) is the leading cause of visual disability and blindness in patients under 60.
  • Gene therapies, while promising, are limited in their application by disease stage and genetic mutation.
  • Small molecule photoswitches conversely hold potential to treat mid- to late-stage RP as a stand-alone drug or in combination with gene therapies.

DALLAS, TX -- December 9th, 2022 -- Stonegate Healthcare has published a new report on Retinitis Pigmentosa (RP) and the pipeline of products in development. The report follows a recent webinar with ophthalmology experts, including a leading researcher and physician, Christine Kay, M.D., Vitreoretinal surgeon and IRD specialist at Vitreoretinal Associates, Eric Daniels, M.D., Chief Development Officer of Kiora Pharmaceuticals (NASDAQ: KPRX) and Ben Shaberman from the Foundation Fighting Blindness.

"There are currently more than 100 drugs in various stages of development for RP worldwide. Development of new treatments is largely being advanced by innovative biotechnology companies. This report breaks down the various approaches of gene therapy, cell therapy, optogenetics, and an emerging class of small molecule photoswitches and their potential to usher in a new era for patients.”



Stonegate Capital Partners is a leading advisory firm founded in 1972. We specialize in capital markets advisory with a focus on institutional investor outreach for public and private companies. Our affiliate, Stonegate Capital Markets (Member FINRA/SIPC) provides a full spectrum of investment banking services and equity research.

Key Takeaways

  • Retinitis Pigmentosa (RP) is the leading cause of visual disability and blindness in patients under 60.
  • Gene therapies, while promising, are limited in their application by disease stage and genetic mutation.
  • Small molecule photoswitches conversely hold potential to treat mid- to late-stage RP as a stand-alone drug or in combination with gene therapies.
Read Full Report on RP

Quotes

“
This report breaks down the various approaches of gene therapy, cell therapy, optogenetics, and an emerging class of small molecule photoswitches.
Shiv Kapoor — Managing Partner Healthcare at Stonegate Capital Partners

Related Bios

Shiv Kapoor
Managing Partner Healthcare at Stonegate Capital Partners
Shiv has a BA in Biochemistry UC Berkeley, and an MBA from the University of Chicago Booth School of Business. He ran the Smith Barney Biotech fund at Citigroup and started Sellside Biotech practices at Montgomery & Co. and Morgan Joseph. In 2008 he was rated among the top three biotechnology analysts by Forbes in the US. His opinion on the US Biotechnology sector has been widely quoted in leading US media including CNN, CNBC, Bloomberg, and Barron’s Guide. In the past decade, Shiv had leading roles as an investor relations and strategy executive at Spectrum pharmaceuticals. He is the founder and CEO of BioRamon Pharmaceuticals, a biopharmaceutical company involved in the discovery and research of oncology medicine.
View Full Bio>>

Contacts

Stonegate Capital Partners
info@stonegateinc.com
(214) 987-4121
General